Pharma Stocks
-
NewAmsterdam Pharma (NAMS) On EU Backing Is The Pullback Leaving Shares Mispriced
NewAmsterdam Pharma (NAMS) is back in focus after regulators in Europe issued a positive opinion on Ubeslo and Evlarco, two…
Read More » -
Why AbbVie Stock Slumped Today
Key Points It posted a second-quarter earnings report that raised some concerns. One was a miss on the consensus bottom-line…
Read More » -
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough
Phathom Pharmaceuticals came into this earnings print with a bruised stock chart, down double digits over the past month and…
Read More » -
Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth
Pharma major Glenmark Pharmaceuticals Ltd on Friday (July 31) reported a 930% year-on-year increase in consolidated net profit to ₹483…
Read More » -
Sun Pharma Q1 Results: Stock falls 3% from highs after US sales miss expectations
Sun Pharma shares declined as much as 3% from the highs of the day on Friday, July 31, after the…
Read More » -
Pharma Mar (BME:PHM) Stock Faces Clinical Setback Despite Royalty Strength
Pharma Mar stock closed at €80.15 after the market absorbed its half year 2026 update, leaving investors weighing a flat…
Read More » -
Vertex Just Paid $10 Billion for Crinetics. Here’s Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target
This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals…
Read More » -
Strong Revenue Growth and …
This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please…
Read More » -
Amneal Pharmaceuticals (AMRX) Wins FDA Nod For Iohexol, Is The Upside Already Priced In?
Amneal Pharmaceuticals (AMRX) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for additional strengths and vial…
Read More » -
Tarsus Pharmaceuticals (TARS) Could Be 38% Undervalued Following Cautious Earnings Expectations
Investors are watching Tarsus Pharmaceuticals (TARS) ahead of its upcoming quarterly report, with expectations for a loss alongside higher revenue…
Read More »
